세계의 NK세포(Natural Killer Cell) 치료제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Natural Killer Cells Therapeutics Market size is anticipated to grow from USD 3.77 Billion in 2024 to USD 11.21 Billion by 2033, showcasing a robust Compound Annual Growth Rate (CAGR) of 12.87% during the forecast period of 2026 to 2033.

The natural killer (NK) cells therapeutics market is poised for significant growth, driven by the increasing recognition of the role of NK cells in cancer immunotherapy. As researchers continue to uncover the potential of NK cells in targeting and eliminating tumor cells, the demand for NK cell-based therapies is surging. Innovations in cell therapy, including the development of engineered NK cells and combination therapies, are enhancing the effectiveness of these treatments, making them more appealing to healthcare providers and patients.

Moreover, the growing emphasis on personalized medicine is influencing the NK cells therapeutics market. As healthcare providers seek to tailor treatments to individual patient profiles, the demand for customized NK cell therapies is rising. This trend is particularly relevant in the context of hematological malignancies and solid tumors, where personalized approaches can improve treatment outcomes and reduce adverse effects.

Furthermore, the increasing focus on research and development in immunotherapy is fostering innovation in the NK cells therapeutics market. Collaborations between bi opharmaceutical companies, research institutions, and clinical centers are driving advancements in NK cell technologies and treatment methodologies, ensuring that new products meet the evolving needs of cancer patients. The growing awareness of the potential benefits of NK cell therapies among healthcare professionals and patients is also contributing to market expansion. In summary, the natural killer cells therapeutics market is set for robust growth, characterized by technological advancements, a focus on personalized treatment approaches, and a commitment to improving cancer care.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

SEGMENTATION COVERED IN THE REPORT

By Therapeutics

• NK Cell Directed Antibodies
• NK Cell Therapies

By Application

• Immunoproliferative Disorders
• Gastrointestinal Diseases
• Cancer
• Other

By End User

• Hospitals
• Research Centers & Institutes
• Other
• COMPANIES PROFILED
• NKT Therapeutics Inc.
• Nkarta Therapeutics Inc.
• Nantkwest Inc.
• Innate Pharma S.A.
• Glycostem Therapeutics BV
• Fortress Biotech
• Fate Therapeutics
• Celgene Corporation
• Affimed N.V.
• Ziopharm Oncology Inc.
• The above list can be customized.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. NATURAL KILLER CELLS THERAPEUTICS INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porters Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutics
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By End User
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET ANALYSIS BY THERAPEUTICS

• 5.1. Overview By Therapeutics
• 5.2. Historical and Forecast Data Analysis By Therapeutics
• 5.3. NK Cell Directed Antibodies Historic and Forecast Sales By Regions
• 5.4. NK Cell Therapies Historic and Forecast Sales By Regions

6. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data Analysis By Application
• 6.3. Immunoproliferative Disorders Historic and Forecast Sales By Regions
• 6.4. Gastrointestinal Diseases Historic and Forecast Sales By Regions
• 6.5. Cancer Historic and Forecast Sales By Regions
• 6.6. Other Historic and Forecast Sales By Regions

7. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET ANALYSIS BY END USER

• 7.1. Overview By End User
• 7.2. Historical and Forecast Data Analysis By End User
• 7.3. Hospitals Historic and Forecast Sales By Regions
• 7.4. Research Centers & Institutes Historic and Forecast Sales By Regions
• 7.5. Other Historic and Forecast Sales By Regions

8. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE NATURAL KILLER CELLS THERAPEUTICS COMPANIES

• 9.1. Natural Killer Cells Therapeutics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF NATURAL KILLER CELLS THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. NKT Therapeutics Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Nkarta Therapeutics Inc.
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Nantkwest Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Innate Pharma S.A.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Glycostem Therapeutics BV
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Fortress Biotech
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Fate Therapeutics
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Celgene Corporation
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Affimed N.V.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Ziopharm Oncology Inc
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies